| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total other income, net | 6,680 | 6,899 | 6,454 | 5,701 |
| Income (loss) before income taxes | -8,704 | -32,918 | 158,494 | - |
| Income tax (provision) benefit | -1,424 | -2,222 | 10,043 | - |
| Net income (loss) | -7,280 | -30,696 | 148,451 | -52,956 |
| Net income (loss) per share of common stock - basic (in usd per share) | -0.18 | -0.76 | 3.66 | -1.41 |
| Net income (loss) per share of common stock - diluted (in usd per share) | -0.18 | -0.76 | 3.62 | -1.41 |
| Weighted average shares of common stock outstanding - basic (in shares) | 40,623,364 | 40,612,907 | 40,559,355 | 37,590,727 |
| Weighted average shares of common stock outstanding - diluted (in shares) | 40,623,364 | 40,612,907 | 41,021,325 | 37,590,727 |
Keros Therapeutics, Inc. (KROS)
Keros Therapeutics, Inc. (KROS)